Jean‐François Baurain

Author

Cliniques Universitaires Saint-Luc ORCID

Also Known As

Baurain, Jean-François, Christof Vulsteke, Felicia Roncolato, Francois P. Duhoux, J -F Baurain, J Baurain, J F Baurain, J-F Baurain, J. Baurain, J. F. Baurain

281

Publications

11.6K

Citations

H-Index

Concepts

All Affiliations

Cliniques Universitaires Saint-Luc UCLouvain Institut Gustave Roussy Memorial Sloan Kettering Cancer Center Heidelberg University

About

Jean‐François Baurain is an author at Cliniques Universitaires Saint-Luc specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	31	3.1K
2	Health Sciences	10	11	931
3	Cell Biology	6	6	487
4	Allergy	1	1	15
5	Diagnostic Sciences	1	1	11

Jean‐François Baurain

Publications

10.7K

Citations

H-Index

Page 1

	Year	Citations
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma Caroline Robert, L. Thomas, Igor Bondarenko, New England Journal of Medicine	2011	4.4K
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma Paul Nathan, Jessica C. Hassel, Piotr Rutkowski, New England Journal of Medicine	2021	806
Characterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory Receptor Hideyuki Ikeda, Bernard Lethé, Frédéric Lehmann, Immunity Tumor ImmunologyCancer ImmunosurveillanceNk Inhibitory ReceptorImmunologyMelanoma	1997	765
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034 Martin J. van den Bent, Alba A. Brandes, R. Rampling, Journal of Clinical Oncology	2009	561
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study Robert L. Coleman, Domenica Lorusso, Christine Gennigens, The Lancet Oncology Tisotumab VedotinCervical CancerMetastatic Cervical CancerMedicineClinical Trials	2021	367
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial Alexander Eggermont, Christian U. Blank, Mario Mandalà, The Lancet Oncology Surgical OncologyMedicineMelanomaImmunologyImmune Checkpoint Inhibitor	2021	364
Neogenesis of Lymphoid Structures and Antibody Responses Occur in Human Melanoma Metastases Arcadi Cipponi, Marjorie Mercier, Teofila Seremet, Cancer Research	2012	244
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma Bart Neyns, Jan Sadones, E. Joosens, Annals of Oncology MedicineMetronomic TherapyRecurrent High-grade GliomaNeurologyHigh-grade Gliomas	2009	239
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma Jessica C. Hassel, Sophie Piperno‐Neumann, Piotr Rutkowski, New England Journal of Medicine	2023	213
Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT) Aurélien Marabelle, Robert Hans Ingemar Andtbacka, Kevin J. Harrington, Annals of Oncology	2018	204

Page 1